Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study.

ABSTRACT:

Background

Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has previously demonstrated its efficacy and safety in chronic kidney disease (CKD) associated with diabetes mellitus. Given its therapeutic potential, finerenone has been preliminarily explored in clinical practice for non-diabetic CKD patients. The effectiveness and safety in this population require further investigation in a real-world setting.

Methods

This retrospective, real-world analysis included non-diabetic CKD patients receiving finerenone. The main clinical outcomes assessed were changes in urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). Serum potassium (sK⁺) levels were also monitored. Data were collected at baseline, and then at 1 

SUBMITTER: Zhou L 

PROVIDER: S-EPMC11534878 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature